Skip directly to content

WEBINAR: Advocates’ Debrief on the Science of Daily F/TAF vs. TDF/FTC as PrEP

tag_webinar_logos_10_1_19.png

Monday, October 7, 2019, 9:00-10:00 am ET

TAG, AVAC, The Well Project and the Women’s Research Initiative (WRI) co-convened this webinar on Monday, October 7.

It was the first in a two-part series, responding to advocates’ desire to better understand the research to date on F/TAF as PrEP, especially as it relates to its safety profile [compared to TDF/FTC] and the lack of robust data in cisgender women. This issue came into greater focus during an August 7 FDA advisory committee meeting at which Gilead’s regulatory submission of F/TAF for PrEP was discussed and debated.

On the webinar, AVAC, TAG, The Well Project and WRI representatives were joined joined by researchers Andrew Hill (Senior Visiting Research Fellow in the Pharmacology Department at Liverpool University) and Monica Gandhi (Professor of Medicine and Associate Division Chief of the Division of HIV, Infectious Diseases, and Global Medicine at UCSF/San Francisco General Hospital). They will share their take on the latest research, contextualize the August 7 discussion, and help to inform an advocacy agenda for next steps.

The webinar was recorded and you can find it online on the AVAC website